MSD Innovation Factory is looking for digital solutions for anaesthesiologists

MSD is looking for innovators to solve 7 health-related challenges. One of them seeks to support anaesthesiologists with their continuous education (e.g. at the operation room) or their team building with surgeons. As a leading pharmaceutical company, MSD is aware of the need to incorporate innovation to deliver the best possible value to healthcare professionals, patients and customers. And that is the MSD Innovation Factory, where three out of the seven finalists (one per challenge) will get the top prize: up to $20,000 each to develop and locally launch the solution.

Co-create with a pharma and go together for unmet needs

MSD is having difficulty to reach anaesthesiologists to share the benefits of using Deep Block (DB) until the end of operations. Deep Block improves surgical conditions as it decreases the movement of the muscles and increases the volume at the operation area.

The main reason for not reaching them is their busy workload and the time spent at operation rooms, where MSD representatives cannot enter. There’s an opportunity for solutions oriented to education, e.g. while at the operating room, communication and team building with surgeons.

Worldwide participants are welcome to apply proposing solutions that will be implemented first in Turkey. The finalist of this challenge will have the opportunity to improve the proposal in collaboration with the local MSD team that proposed the challenge.

Find all the info about the anaesthesiologists challenge: https://www.msdinnovationfactory.com/challenges/anestouch/

Do you have a solution? Apply now!
www.msdinnovationfactory.com

How MSD Innovation Factory works

The innovation factory initiative aims to give support to the companies that come up with the best ideas to solve one of the 7 challenges identified in the EEMEA Region (Eastern Europe, Middle East and Africa) by local MSD teams.

The selection is done in four steps:

  • Solutions submitted before 31st October are reviewed by the challenge owners (the local MSD teams).
  • Each country will select the best solution for its proposed challenge.
  • During co-creation sessions the selected company and the local MSD team will work together in an improved proposal to be jointly presented in a Final event.
  • At the Final event in January 2018, the 7 finalists will pitch their solution in front of a senior jury from MSD. The jury will award 3 winners.

The prizes

Each of the 3 winners will receive the following:
  • Up to $20,000 to pilot their solution in the challenge-related local market.
  • Support from MSD local team to connect with the local ecosystem (eg. medical professional associations), deal with potential regulatory issues and disseminate leveraging MSD local channels. It will also contribute with expertise and business know-how.
  • If the local launch is a success after 12 months, its outcomes will be globally shared within MSD to investigate further implementation beyond the initial market.

All 7 finalists will get a 500€ grant to cover travel expenses to attend the Final event in Istanbul, and the opportunity to optimize their proposal in collaboration with the local MSD team that proposed the challenge. They will also receive visibility through the initiative communication channels.

MSD is a global healthcare company with a 125-year history committed to being the premier, research-intensive biopharmaceutical company and are dedicated to providing leading innovations and solutions for today and the future.

Applications until 31 October

Do you have a solution? Apply now!
www.msdinnovationfactory.com

Most Popular Now

Novo Nordisk announces plans to transform its appr…

Novo Nordisk announced plans to restructure its Research & Development (R&D) organisation to accelerate the expansion and diversification of its pipeline across serious c...

The Merck Accelerator Program 2019

The Merck Accelerator is looking for real partners so that you can work together in shaping the future. With programs in the headquarters in Germany, in China and the Sat...

World's largest Alzheimer's survey reveals most ad…

Amgen (NASDAQ:AMGN), Novartis and Banner Alzheimer's Institute (BAI), in association with Alzheimer's Disease International (ADI), announced results from the largest glob...

Imfinzi is the first immunotherapy to demonstrate …

AstraZeneca and MedImmune, its global biologics research and development arm, have presented data on overall survival (OS) in the Phase III PACIFIC trial of Imfinzi durin...

Pre-clinical success for a universal flu vaccine o…

Researchers from the University of Oxford's Department of Zoology have demonstrated pre-clinical success for a universal flu vaccine in a new paper published in Nature Co...

Discovery could explain failed clinical trials for…

Researchers at King's College London have discovered a vicious feedback loop underlying brain degeneration in Alzheimer's disease which may explain why so many drug trial...

Global survey reveals that physicians need more in…

Results from a new global survey revealed that more than one-third (36%) of the 310 physicians surveyed do not think they have sufficient information required to make inf...

Aspirin found not to prolong healthy aging

Taking a low-dose aspirin daily does not prolong healthy living in older adults, according to findings from the ASPirin in Reducing Events in the Elderly (ASPREE) trial p...

The Lancet Respiratory Medicine publishes first Ph…

AstraZeneca today announced publication of results from the KRONOS Phase III trial which evaluated the efficacy and safety of triple combination therapy PT010 (budesonide...

In clinical trials, new antibody therapy controls …

Thanks to improvements in antiretroviral therapy, HIV is now a manageable condition. Yet even the best drugs do not entirely eliminate the virus, which latently lingers i...

FDA approves first treatment for advanced form of …

The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squam...

Clinical gene discovery program solves 30 medical …

A table in a recently published paper tells the story of 30 families who have, sometimes after years of searching, finally received an answer about the condition that has...